146 related articles for article (PubMed ID: 27244881)
1. Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic.
Ohman KA; Hashim YM; Vangveravong S; Nywening TM; Cullinan DR; Goedegebuure SP; Liu J; Van Tine BA; Tiriac H; Tuveson DA; DeNardo DG; Spitzer D; Mach RH; Hawkins WG
Oncotarget; 2016 Jun; 7(23):33529-41. PubMed ID: 27244881
[TBL] [Abstract][Full Text] [Related]
2. Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy.
Kashiwagi H; McDunn JE; Simon PO; Goedegebuure PS; Xu J; Jones L; Chang K; Johnston F; Trinkaus K; Hotchkiss RS; Mach RH; Hawkins WG
Mol Cancer; 2007 Jul; 6():48. PubMed ID: 17631687
[TBL] [Abstract][Full Text] [Related]
3. Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134.
Hashim YM; Spitzer D; Vangveravong S; Hornick MC; Garg G; Hornick JR; Goedegebuure P; Mach RH; Hawkins WG
Mol Oncol; 2014 Jul; 8(5):956-67. PubMed ID: 24731702
[TBL] [Abstract][Full Text] [Related]
4. Incorporation of a selective sigma-2 receptor ligand enhances uptake of liposomes by multiple cancer cells.
Zhang Y; Huang Y; Zhang P; Gao X; Gibbs RB; Li S
Int J Nanomedicine; 2012; 7():4473-85. PubMed ID: 22927761
[TBL] [Abstract][Full Text] [Related]
5. Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells.
McDonald ES; Mankoff J; Makvandi M; Chu W; Chu Y; Mach RH; Zeng C
Biochem Biophys Res Commun; 2017 May; 486(3):788-795. PubMed ID: 28347815
[TBL] [Abstract][Full Text] [Related]
6. Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) induce cell death via mitochondrial superoxide production and caspase activation in pancreatic cancer.
Pati ML; Hornick JR; Niso M; Berardi F; Spitzer D; Abate C; Hawkins W
BMC Cancer; 2017 Jan; 17(1):51. PubMed ID: 28086830
[TBL] [Abstract][Full Text] [Related]
7. Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer.
Garg G; Vangveravong S; Zeng C; Collins L; Hornick M; Hashim Y; Piwnica-Worms D; Powell MA; Mutch DG; Mach RH; Hawkins WG; Spitzer D
Mol Cancer; 2014 Mar; 13():50. PubMed ID: 24602489
[TBL] [Abstract][Full Text] [Related]
8. Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signaling.
Spitzer D; Simon PO; Kashiwagi H; Xu J; Zeng C; Vangveravong S; Zhou D; Chang K; McDunn JE; Hornick JR; Goedegebuure P; Hotchkiss RS; Mach RH; Hawkins WG
Cancer Res; 2012 Jan; 72(1):201-9. PubMed ID: 22065721
[TBL] [Abstract][Full Text] [Related]
9. Lysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic cancer.
Hornick JR; Vangveravong S; Spitzer D; Abate C; Berardi F; Goedegebuure P; Mach RH; Hawkins WG
J Exp Clin Cancer Res; 2012 May; 31(1):41. PubMed ID: 22551149
[TBL] [Abstract][Full Text] [Related]
10. The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine.
Hornick JR; Xu J; Vangveravong S; Tu Z; Mitchem JB; Spitzer D; Goedegebuure P; Mach RH; Hawkins WG
Mol Cancer; 2010 Nov; 9():298. PubMed ID: 21092190
[TBL] [Abstract][Full Text] [Related]
11. Erastin, a ferroptosis-inducing agent, sensitized cancer cells to X-ray irradiation via glutathione starvation in vitro and in vivo.
Shibata Y; Yasui H; Higashikawa K; Miyamoto N; Kuge Y
PLoS One; 2019; 14(12):e0225931. PubMed ID: 31800616
[TBL] [Abstract][Full Text] [Related]
12. Design and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cells.
Wu B; Wang S; De SK; Barile E; Quinn BA; Zharkikh I; Purves A; Stebbins JL; Oshima RG; Fisher PB; Pellecchia M
Chem Biol; 2015 Jul; 22(7):876-887. PubMed ID: 26165155
[TBL] [Abstract][Full Text] [Related]
13. Multifunctional thiosemicarbazones and deconstructed analogues as a strategy to study the involvement of metal chelation, Sigma-2 (σ
Pati ML; Niso M; Spitzer D; Berardi F; Contino M; Riganti C; Hawkins WG; Abate C
Eur J Med Chem; 2018 Jan; 144():359-371. PubMed ID: 29287249
[TBL] [Abstract][Full Text] [Related]
14. The sigma-2 receptor as a therapeutic target for drug delivery in triple negative breast cancer.
Makvandi M; Tilahun ED; Lieberman BP; Anderson RC; Zeng C; Xu K; Hou C; McDonald ES; Pryma DA; Mach RH
Biochem Biophys Res Commun; 2015 Nov; 467(4):1070-5. PubMed ID: 26453012
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands.
Hornick JR; Spitzer D; Goedegebuure P; Mach RH; Hawkins WG
Surgery; 2012 Sep; 152(3 Suppl 1):S152-6. PubMed ID: 22763259
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Erastin as a Therapeutic Agent Under Hypoxic Conditions in Pancreatic Cancer Cells.
Owada S; Endo H; Shida Y; Kinoue T; Furuya H; Tatemichi M
Anticancer Res; 2021 Dec; 41(12):6051-6059. PubMed ID: 34848459
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinase-9 (MMP-9) as an activator of nanosystems for targeted drug delivery in pancreatic cancer.
Grünwald B; Vandooren J; Locatelli E; Fiten P; Opdenakker G; Proost P; Krüger A; Lellouche JP; Israel LL; Shenkman L; Comes Franchini M
J Control Release; 2016 Oct; 239():39-48. PubMed ID: 27545397
[TBL] [Abstract][Full Text] [Related]
18. Using SV119-gold nanocage conjugates to eradicate cancer stem cells through a combination of photothermal and chemo therapies.
Sun T; Wang Y; Wang Y; Xu J; Zhao X; Vangveravong S; Mach RH; Xia Y
Adv Healthc Mater; 2014 Aug; 3(8):1283-91. PubMed ID: 24677807
[TBL] [Abstract][Full Text] [Related]
19. Potential applications for sigma receptor ligands in cancer diagnosis and therapy.
van Waarde A; Rybczynska AA; Ramakrishnan NK; Ishiwata K; Elsinga PH; Dierckx RA
Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2703-14. PubMed ID: 25173780
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticle formulation of ormeloxifene for pancreatic cancer.
Khan S; Chauhan N; Yallapu MM; Ebeling MC; Balakrishna S; Ellis RT; Thompson PA; Balabathula P; Behrman SW; Zafar N; Singh MM; Halaweish FT; Jaggi M; Chauhan SC
Biomaterials; 2015; 53():731-43. PubMed ID: 25890768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
